Stoke Therapeutics director Edward Kaye resigns; board appoints Alexander Cumbo to Class III seat

Stoke Therapeutics, Inc.

Edward M. Kaye, M.D. resigned as a Class III director and Research and Development Committee member effective Sept. 23, 2026; resignation was not due to any disagreement with Stoke Therapeutics.
The board appointed Alexander (Bo) Cumbo as a Class III director effective Sept. 23, 2026, to fill Kaye's vacancy; his term expires at the 2028 annual stockholders meeting.
Cumbo is independent under SEC and Nasdaq rules and has no Item 404(a) related-party transactions with Stoke; he entered Stoke's standard director indemnity agreement.
Under Stoke's non-employee director compensation program, Cumbo receives a $45,000 annual cash retainer and an initial option for 39,674 shares with a target grant date fair value of about $724,000.
The option vests in twelve substantially equal quarterly installments on each quarterly anniversary of the grant date.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.